Unknown

Dataset Information

0

Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis.


ABSTRACT: Scleroderma-associated pulmonary fibrosis (SSc-PF) and idiopathic pulmonary fibrosis (IPF) are two of many chronic fibroproliferative diseases that are responsible for nearly 45% of all deaths in developed countries. While sharing several pathobiological characteristics, they also have very distinct features. Currently no effective anti-fibrotic treatments exist that can halt the progression of PF or reverse it. Our goal is to uncover potential gene targets for the development of anti-fibrotic therapies efficacious in both diseases, and those specific to SSc-PF, by identifying universal pathways and molecules driving fibrosis in SSc-PF and IPF tissues as well as those unique to SSc-PF. Using DNA microarray data, a meta-analysis of the differentially expressed (DE) genes in SSc-PF and IPF lung tissues (diseased vs. normal) was performed followed by a full systems level analysis of the common and unique transcriptomic signatures obtained. Protein-protein interaction networks were generated to identify hub proteins and explore the data using the centrality principle. Our results suggest that therapeutic strategies targeting IL6 trans-signaling, IGFBP2, IGFL2, and the coagulation cascade may be efficacious in both SSc-PF and IPF. Further, our data suggest that the expression of matrikine-producing collagens is also perturbed in PF. Lastly, an overall perturbation of bioenergetics, specifically between glycolysis and fatty acid metabolism, was uncovered in SSc-PF. Our findings provide insights into potential targets for the development of anti-fibrotic therapies that could be effective in both IPF and SSc-PF.

SUBMITTER: Renaud L 

PROVIDER: S-EPMC7075854 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis.

Renaud Ludivine L   da Silveira Willian A WA   Takamura Naoko N   Hardiman Gary G   Feghali-Bostwick Carol C  

Frontiers in immunology 20200310


Scleroderma-associated pulmonary fibrosis (SSc-PF) and idiopathic pulmonary fibrosis (IPF) are two of many chronic fibroproliferative diseases that are responsible for nearly 45% of all deaths in developed countries. While sharing several pathobiological characteristics, they also have very distinct features. Currently no effective anti-fibrotic treatments exist that can halt the progression of PF or reverse it. Our goal is to uncover potential gene targets for the development of anti-fibrotic t  ...[more]

Similar Datasets

| S-EPMC2118688 | biostudies-literature
| S-EPMC6509019 | biostudies-literature
| S-EPMC8467216 | biostudies-literature
| S-EPMC8999630 | biostudies-literature
| S-EPMC3961515 | biostudies-literature
| S-EPMC3139818 | biostudies-literature
| S-EPMC2822976 | biostudies-literature
| S-EPMC2778162 | biostudies-literature
2013-06-21 | E-GEOD-48149 | biostudies-arrayexpress
| S-EPMC10067542 | biostudies-literature